Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q06495
UPID:
NPT2A_HUMAN
Alternative names:
Na(+)-dependent phosphate cotransporter 2A; NaPi-3; Sodium/phosphate cotransporter 2A; Solute carrier family 34 member 1
Alternative UPACC:
Q06495; B4DPE3
Background:
Sodium-dependent phosphate transport protein 2A, also known as Na(+)-dependent phosphate cotransporter 2A, NaPi-3, and Solute carrier family 34 member 1, plays a crucial role in phosphate homeostasis. It actively transports phosphate into cells via Na(+) cotransport in the renal brush border membrane, with a Na(+):Pi stoichiometry of 3:1, making the process electrogenic.
Therapeutic significance:
This protein's malfunction is linked to diseases such as Nephrolithiasis/osteoporosis, hypophosphatemic, 1, Fanconi renotubular syndrome 2, and Hypercalcemia, infantile, 2. These conditions underscore the protein's critical role in renal phosphate absorption and the potential for targeted therapies to address phosphate homeostasis disorders.